 |
 |
 |
 |
 |
 |
 |
Zengen Inc. Founded in 1999, Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its proprietary peptide technologies. Zengen is currently conducting Phase I/II clinical trials for CZEN 002, one of the Company’s proprietary peptide molecules, for the treatment of vulvovaginal candidiasis, commonly known as vaginal yeast infection. For more information, please visit www.zengen.com.
|
|
|
|
 |
|
Copyright @ 2005 DragonVenture, Inc. All rights reserved.